ZyVersa Therapeutics Key Executives
This section highlights ZyVersa Therapeutics's key executives, including their titles and compensation details.
Find Contacts at ZyVersa Therapeutics
(Showing 0 of )
ZyVersa Therapeutics Earnings
This section highlights ZyVersa Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
$0.61
Stock Price
$1.56M
Market Cap
7
Employees
Weston, FL
Location
Financial Statements
Access annual & quarterly financial statements for ZyVersa Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $10.40K | $10.40K | $10.40K | $10.40K |
| Gross Profit | $- | $-10.40K | $-10.40K | $-10.40K | $-10.40K |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $1.78B | $3.21M | $5.41M | $2.12M | $6.47M |
| General and Administrative Expenses | $7.36B | $11.21B | $7.61M | $5.58M | $5.36M |
| Selling and Marketing Expenses | $- | $-11.20B | $- | $- | $- |
| Selling General and Administrative Expenses | $7.36B | $11.20M | $7.61M | $5.58M | $5.36M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $9.14B | $14.41M | $13.01M | $7.70M | $11.83M |
| Cost and Expenses | $- | $14.42M | $13.01M | $7.70M | $11.83M |
| Interest Income | $- | $- | $428 | $821 | $516 |
| Interest Expense | $269.86M | $-457.00K | $427.54K | $821.37K | $516.45K |
| Depreciation and Amortization | $- | $10.40K | $10.40K | $10.40K | $10.40K |
| EBITDA | $-9.14B | $-107.74M | $-11.67M | $-7.25M | $-12.16M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-9.14B | $-14.42M | $-13.01M | $-7.70M | $-11.83M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $-283.35M | $-93.33M | $-2.37M | $-379.79K | $-850.11K |
| Income Before Tax | $-9.42B | $-107.75M | $-14.05M | $-8.08M | $-12.68M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $-6.75M | $-9.46M | $745.05M | $821.37K | $516.45K |
| Net Income | $-9.41B | $-98.30M | $-759.10M | $-8.91M | $-13.20M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-848.03 | $-1089.67 | $-930.25 | $-173.66 | $-272.45 |
| EPS Diluted | $-848.03 | $-1089.67 | $-930.25 | $-173.66 | $-272.45 |
| Weighted Average Shares Outstanding | 11.10M | 97.50K | 25.95K | 46.55K | 46.55K |
| Weighted Average Shares Outstanding Diluted | 11.10M | 97.50K | 25.95K | 46.55K | 46.55K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.08K | $- | $- | $- | $15.60K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $13.04K | $- | $2.60K | $10.44K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $- | $2.60K | $2.60K | $2.60K |
| Gross Profit | $13.04K | $- | $-2.60K | $-10.44K | $13.00K | $-2.60K | $-2.60K | $-2.60K | $-2.60K | $-2.60K | $-2.60K | $-2.60K | $- | $-2.60K | $-2.60K | $-2.60K |
| Gross Profit Ratio | 50.00% | 0.00% | - | - | 83.33% | - | - | - | - | - | - | - | - | - | - | - |
| Research and Development Expenses | $1.78B | $436.04K | $709.05K | $512.94K | $257.11K | $673.94K | $1.22M | $1.06M | $1.29M | $2.33M | $719.39K | $1.07M | $633.97K | $406.95K | $496.51K | $586.85K |
| General and Administrative Expenses | $1.17M | $1.83B | $2.04M | $2.31M | $1.52M | $2.23M | $3.93M | $3.54M | $3.08M | $1.06M | $1.16M | $2.30M | $1.14M | $1.71M | $1.32K | $1.34K |
| Selling and Marketing Expenses | $7.35B | $-1.83B | $-2.60K | $-2.31B | $-2.60K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.35M | $1.37M |
| Selling General and Administrative Expenses | $7.35B | $1.83M | $2.04M | $2.30M | $1.52M | $2.23M | $3.93M | $3.54M | $3.08M | $1.06M | $1.16M | $2.30M | $1.14M | $1.71M | $1.35M | $1.37M |
| Other Expenses | $- | $- | $- | $- | $93.25B | $- | $81.17M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $9.13B | $2.27M | $2.75M | $2.82M | $1.77M | $2.90M | $5.15M | $4.59M | $4.37M | $3.40M | $1.88M | $3.37M | $1.78M | $2.11M | $1.85M | $1.96M |
| Cost and Expenses | $9.13B | $2.27M | $2.75M | $2.83M | $1.78M | $2.90M | $5.15M | $4.59M | $4.37M | $3.40M | $1.88M | $3.37M | $1.78M | $2.11M | $1.85M | $1.96M |
| Interest Income | $269.86M | $- | $- | $- | $- | $0 | $0 | $1.08K | $- | $69 | $105.11K | $4.45K | $- | $- | $- | $170 |
| Interest Expense | $269.99M | $131.63K | $58 | $101 | $- | $210 | $314 | $- | $49.72K | $69.35K | $140.40K | $168.06K | $204.72K | $225.49K | $- | $- |
| Depreciation and Amortization | $-14.77K | $1.73K | $2.60K | $10.44K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K |
| EBITDA | $-1.29M | $-2.27M | $-2.75M | $-2.82M | $-13.93M | $-2.90M | $-5.15M | $-4.59M | $-5.37M | $-3.62M | $-1.88M | $-3.58M | $-1.77M | $-1.65M | $-1.85M | $-1.96M |
| EBITDA Ratio | -4933.66% | - | - | - | -89307.49% | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-9.13B | $-2.27M | $-2.75M | $-2.83M | $-1.78M | $-2.90M | $-86.33M | $-4.59M | $-4.37M | $-3.40M | $-1.88M | $-3.37M | $-1.78M | $-2.11M | $-1.85M | $-1.96M |
| Operating Income Ratio | -35006456.63% | - | - | - | -11386.03% | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $9.13B | $-2.40B | $-58 | $-101 | $-12.16M | $-210 | $-81.18M | $1.08K | $-2.39M | $-297.45K | $-120.80K | $-380.16K | $-192.52K | $234.50K | $-244.44K | $-177.33K |
| Income Before Tax | $-1.42M | $-2.40B | $-2.75M | $-2.83M | $-13.93M | $-2.90M | $-86.33M | $-4.59M | $-4.60M | $-3.69M | $-2.00M | $-3.75M | $-1.97M | $-1.88M | $-2.10M | $-2.14M |
| Income Before Tax Ratio | -5463.08% | - | - | - | -89324.15% | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $-6.75M | $- | $9.71K | $1 | $-596.07K | $-485 | $-7.81M | $-1.05M | $186.40K | $47.55K | $-210.23K | $-85.50K | $192.52K | $1 | $- | $- |
| Net Income | $-1.42M | $-2.40B | $-2.76M | $-2.83M | $-13.34M | $-2.90M | $-78.51M | $-3.54M | $-4.79M | $-3.74M | $-1.79M | $-3.66M | $-1.97M | $-1.88M | $-2.10M | $-2.14M |
| Net Income Ratio | -5451.72% | - | - | - | -85503.21% | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-0.13 | $-0.24 | $-3.31 | $-4.53 | $-32.92 | $-33.16 | $-1694.14 | $-135.88 | $-180.25 | $-287.36 | $-50.17 | $-80.52 | $-8.33 | $-40.38 | $-45.00 | $-45.97 |
| EPS Diluted | $-0.13 | $-0.24 | $-3.31 | $-4.53 | $-32.92 | $-33.16 | $-1694.14 | $-135.88 | $-180.25 | $-287.36 | $-50.17 | $-80.52 | $-8.33 | $-40.38 | $-45.00 | $-45.97 |
| Weighted Average Shares Outstanding | 11.10M | 9.88M | 834.91K | 623.60K | 405.20K | 88.51K | 51.02K | 26.08K | 25.95K | 46.55K | 46.55K | 46.55K | 28.65K | 46.55K | 46.55K | 46.55K |
| Weighted Average Shares Outstanding Diluted | 11.10M | 9.88M | 834.91K | 623.60K | 405.20K | 88.51K | 51.02K | 26.08K | 25.95K | 46.55K | 46.55K | 46.55K | 28.65K | 46.55K | 46.55K | 46.55K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.53M | $3.14M | $5.90M | $328.58K | $174.67K |
| Short Term Investments | $1.53B | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.53B | $3.14M | $5.90M | $328.58K | $174.67K |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $184.87M | $215.46K | $460.35K | $483.20K | $164.44K |
| Total Current Assets | $1.72B | $3.35M | $6.36M | $811.78K | $339.11K |
| Property Plant Equipment Net | $- | $14.77K | $115.70K | $27.73K | $38.13K |
| Goodwill | $- | $- | $11.90M | $- | $- |
| Intangible Assets | $18.65M | $18.65M | $100.09M | $- | $- |
| Goodwill and Intangible Assets | $18.65M | $18.65M | $111.98M | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $18.86B | $98.48K | $46.66K | $286.66K | $308.32K |
| Total Non-Current Assets | $18.88B | $18.76M | $112.14M | $314.39K | $346.46K |
| Other Assets | $- | $- | $-0 | $- | $- |
| Total Assets | $20.60B | $22.11M | $118.51M | $1.13M | $685.57K |
| Account Payables | $9.34M | $8.43M | $6.03M | $2.00M | $2.31M |
| Short Term Debt | $- | $8.66K | $108.76K | $9.15M | $2.13M |
| Tax Payables | $- | $- | $106.68K | $- | $- |
| Deferred Revenue | $- | $- | $- | $765.68K | $1.18M |
| Other Current Liabilities | $1.89M | $1.75M | $1.95M | $2.46M | $3.09M |
| Total Current Liabilities | $11.23M | $10.19M | $8.19M | $13.63M | $7.56M |
| Long Term Debt | $- | $- | $- | $- | $1.69M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $851.66K | $844.91K | $10.32M | $- | $- |
| Other Non-Current Liabilities | $850.81M | $- | $- | $- | $- |
| Total Non-Current Liabilities | $851.66M | $844.91K | $10.32M | $- | $1.69M |
| Other Liabilities | $11.22B | $- | $- | $- | $- |
| Total Liabilities | $12.08B | $11.04M | $18.51M | $13.63M | $9.24M |
| Preferred Stock | $1 | $1 | $2 | $331.33K | $331.33K |
| Common Stock | $251 | $405 | $902 | $242 | $242 |
| Retained Earnings | $-112.63B | $-103.22M | $-4.92M | $-52.90M | $-44.81M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-331.33K | $-331.33K |
| Other Total Stockholders Equity | $121.15B | $114.29M | $104.91M | $40.73M | $36.59M |
| Total Stockholders Equity | $8.52B | $11.07M | $99.99M | $-12.50M | $-8.56M |
| Total Equity | $8.52B | $11.07M | $99.99M | $-12.50M | $-8.56M |
| Total Liabilities and Stockholders Equity | $20.60B | $22.11M | $118.51M | $1.13M | $685.57K |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $20.60B | $22.11M | $118.51M | $1.13M | $685.57K |
| Total Investments | $1.53B | $- | $- | $- | $- |
| Total Debt | $- | $8.66K | $108.76K | $9.15M | $3.82M |
| Net Debt | $-1.53M | $-3.13M | $-5.79M | $8.82M | $3.64M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.53M | $122.92K | $119.49K | $2.03M | $3.14M | $1.58M | $228.69K | $1.28M | $5.90M | $602.75K | $31.46K | $347.93K | $328.58K | $686.50K | $702.48K | $-175 |
| Short Term Investments | $1.53B | $122.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $349 |
| Cash and Short Term Investments | $1.53B | $122.92M | $119.49K | $2.03M | $3.14M | $1.58M | $228.69K | $1.28M | $5.90M | $602.75K | $31.46K | $347.93K | $328.58K | $686.50K | $702.48K | $175 |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $184.87M | $267.49M | $521.91K | $866.48K | $215.46K | $426.52K | $886.91K | $1.56M | $460.35K | $1.60M | $1.72M | $903.56K | $483.20K | $- | $- | $- |
| Total Current Assets | $1.72B | $390.42M | $641.39K | $2.90M | $3.35M | $2.01M | $1.12M | $2.83M | $6.36M | $2.20M | $1.75M | $1.25M | $811.78K | $686.50K | $702.48K | $175 |
| Property Plant Equipment Net | $- | $- | $1.73K | $4.33K | $14.77K | $40.61K | $66.03K | $91.06K | $115.70K | $19.93K | $22.53K | $25.13K | $27.73K | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $11.90B | $11.90M | $11.90M | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $18.65M | $18.65M | $18.65M | $18.65M | $18.65M | $30.81M | $30.81M | $100.09M | $100.09M | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $18.65M | $18.65M | $18.65M | $18.65M | $18.65M | $30.81M | $30.81M | $111.98M | $111.98M | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $78.91M | $- | $- | $75.75M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $18.86B | $385.61K | $178.48K | $98.48K | $98.48K | $- | $- | $46.66K | $46.66K | $-78.79M | $166.66K | $226.66K | $-75.46M | $402.41K | $320.61K | $227.84K |
| Total Non-Current Assets | $18.88B | $19.03M | $18.83M | $18.75M | $18.76M | $30.85M | $30.87M | $112.12M | $112.14M | $146.59K | $189.19K | $251.79K | $314.39K | $402.41K | $320.61K | $227.84K |
| Other Assets | $- | $-390.02M | $- | $- | $- | $- | $0 | $- | $-0 | $- | $- | $-0 | $- | $- | $- | $492 |
| Total Assets | $20.60B | $19.42M | $19.47M | $21.65M | $22.11M | $32.85M | $31.99M | $114.95M | $118.51M | $2.35M | $1.94M | $1.50M | $1.13M | $1.09M | $1.02M | $228.50K |
| Account Payables | $9.34M | $9.28M | $8.32M | $8.13M | $8.43M | $8.90M | $8.14M | $6.38M | $6.03M | $6.50M | $4.20M | $3.23M | $2.00M | $- | $- | $- |
| Short Term Debt | $- | $- | $- | $- | $8.66K | $34.35K | $119.25K | $169.01K | $108.76K | $3.96M | $9.19M | $9.18M | $9.15M | $719.08K | $719.08K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $129.92K | $129.92K | $106.68K | $106.68K | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $2.27M | $1.76M | $- | $- | $12.08K | $13.77K | $15.47K | $765.68K | $- | $- | $- |
| Other Current Liabilities | $1.89M | $2.26M | $1.68M | $1.45M | $1.75M | $2.65M | $2.09M | $1.92M | $1.95M | $3.67M | $3.75M | $2.98M | $1.71M | $349.83K | $283.84K | $228.94K |
| Total Current Liabilities | $11.23M | $11.54M | $9.99M | $9.58M | $10.19M | $11.71M | $10.48M | $8.58M | $8.19M | $14.15M | $17.16M | $15.42M | $13.63M | $1.07M | $1.00M | $228.94K |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $851.66K | $854.62K | $854.62K | $844.91K | $844.91K | $1.44M | $1.44M | $9.28M | $10.32M | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $850.81M | $853.77M | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $719.08K | $719.08K | $- |
| Total Non-Current Liabilities | $851.66M | $854.62M | $854.62K | $844.91K | $844.91K | $1.44M | $1.44M | $9.28M | $10.32M | $10.47M | $13.39M | $3.38M | $11.15M | $719.08K | $719.08K | $- |
| Other Liabilities | $11.22B | $-853.77M | $1 | $- | $1 | $- | $0 | $- | $- | $-10.47M | $-13.39M | $-3.38M | $-11.15M | $-719.08K | $-719.08K | $- |
| Total Liabilities | $12.08B | $12.40M | $10.85M | $10.43M | $11.04M | $13.15M | $11.93M | $17.86M | $18.51M | $14.15M | $17.16M | $15.42M | $13.63M | $1.07M | $1.00M | $228.94K |
| Preferred Stock | $1 | $1 | $1 | $1 | $1 | $1 | $1 | $2 | $2 | $23 | $1 | $331.33K | $75.75M | $- | $- | $- |
| Common Stock | $251 | $107 | $83 | $83 | $405 | $4.35K | $2.37K | $922 | $902 | $242 | $242 | $242 | $242 | $216 | $216 | $216 |
| Retained Earnings | $-112.63B | $-111.21M | $-108.81M | $-106.05M | $-103.22M | $-89.88M | $-86.98M | $-8.47M | $-4.92M | $-62.34M | $-58.65M | $-56.65M | $-52.90M | $-2.07K | $-1.90K | $-1.11K |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-1.00K | $-405 | $- | $-104.15B | $- | $- | $- | $- | $-242 | $-75.75M | $- | $- | $- |
| Other Total Stockholders Equity | $121.15B | $118.24M | $117.43M | $117.27M | $114.29M | $109.58M | $107.04M | $105.56M | $104.91M | $50.54M | $43.43M | $42.40M | $115.82M | $21.85K | $21.85K | $-7.78K |
| Total Stockholders Equity | $8.52B | $7.03M | $8.62M | $11.22M | $11.07M | $19.70M | $20.06M | $97.10M | $99.99M | $-11.80M | $-15.22M | $-13.91M | $-12.50M | $19.99K | $20.17K | $-8.89K |
| Total Equity | $8.52B | $7.03M | $8.62M | $11.22M | $11.07M | $19.70M | $20.06M | $97.10M | $99.99M | $-11.80M | $-15.22M | $-13.91M | $-12.50M | $19.99K | $20.17K | $-8.89K |
| Total Liabilities and Stockholders Equity | $20.60B | $19.42M | $19.47M | $21.65M | $22.11M | $32.85M | $31.99M | $114.95M | $118.51M | $2.35M | $1.94M | $1.50M | $1.13M | $1.09M | $1.02M | $228.50K |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $20.60B | $19.42M | $19.47M | $21.65M | $22.11M | $32.85M | $31.99M | $114.95M | $118.51M | $2.35M | $1.94M | $1.50M | $1.13M | $1.09M | $1.02M | $228.50K |
| Total Investments | $1.53B | $122.80M | $- | $- | $- | $- | $- | $- | $- | $78.91M | $- | $- | $75.75M | $- | $- | $349 |
| Total Debt | $- | $- | $- | $- | $8.66K | $34.35K | $59.62K | $84.51K | $108.76K | $3.96M | $9.19M | $9.18M | $9.15M | $719.08K | $719.08K | $- |
| Net Debt | $-1.53M | $-122.92K | $-119.49K | $-2.03M | $-3.13M | $-1.54M | $-169.07K | $-1.19M | $-5.79M | $3.36M | $9.16M | $8.84M | $8.82M | $32.58K | $16.60K | $175 |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-9.41B | $-98.30M | $-14.05M | $-8.08M | $-12.68M |
| Depreciation and Amortization | $6.93M | $10.40K | $9.87K | $10.40K | $10.40K |
| Deferred Income Tax | $6.75M | $-9.48M | $-745.05K | $-441.58K | $333.66K |
| Stock Based Compensation | $705.57M | $1.19M | $3.52M | $4.14M | $3.83M |
| Change in Working Capital | $929.88K | $2.60M | $8.29M | $-1.02M | $3.11M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $750.57K | $2.41M | $6.62M | $-311.86K | $-601.47K |
| Other Working Capital | $179.31K | $194.51K | $1.67M | $-708.45K | $3.71M |
| Other Non Cash Items | $1.13B | $95.25M | $1.47M | $317.83K | $288.37K |
| Net Cash Provided by Operating Activities | $-7.56B | $-8.72M | $-1.49M | $-5.08M | $-5.11M |
| Investments in Property Plant and Equipment | $- | $-1 | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $1.69M |
| Common Stock Issued | $196.77M | $18.11M | $1.87M | $- | $3.00M |
| Common Stock Repurchased | $- | $-10.70M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.95B | $-12.15M | $1.96M | $5.23M | $-126.40K |
| Net Cash Used Provided by Financing Activities | $5.95B | $5.96M | $1.87K | $5.23M | $4.56M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-1.61B | $-2.76M | $370.74K | $153.91K | $-549.76K |
| Cash at End of Period | $1.53B | $3.14M | $699.32K | $328.58K | $174.67K |
| Cash at Beginning of Period | $3.14B | $5.90M | $328.58K | $174.67K | $724.43K |
| Operating Cash Flow | $-7.56B | $-8.72M | $-1.49M | $-5.08M | $-5.11M |
| Capital Expenditure | $- | $-1 | $- | $- | $- |
| Free Cash Flow | $-7.56B | $-8.72M | $-1.49M | $-5.08M | $-5.11M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-9.41B | $-2.40M | $-2.76M | $-2.83M | $-13.34M | $-2.90M | $-78.51M | $-3.54M | $-4.60M | $-3.69M | $-2.00M | $-3.75M | $-1.97M | $-1.88M | $-2.10M | $-2.14M |
| Depreciation and Amortization | $- | $6.93M | $2.60K | $10.44K | $2.60K | $2.60K | $2.60K | $2.60K | $2.07K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K | $2.60K |
| Deferred Income Tax | $-2.96K | $9.71M | $9.71K | $- | $-596.07K | $-485 | $-7.84M | $-1.05M | $-745.05K | $- | $- | $- | $-12.20K | $-459.99K | $- | $- |
| Stock Based Compensation | $447.74M | $257.44M | $160.66K | $223.57K | $296.71K | $243.04K | $365.74K | $287.46K | $393.09K | $494.02K | $695.94K | $1.94M | $821.82K | $1.40M | $1.03K | $896 |
| Change in Working Capital | $-1.01M | $1.59M | $676.68K | $-1.26M | $-1.40M | $1.70M | $2.61M | $-310.56K | $3.52M | $2.58M | $1.03M | $1.17M | $474.81K | $153.59K | $-540.91K | $-1.11M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $74.39K | $791.25K | $188.76K | $-303.84K | $-465.95K | $753.50K | $1.76M | $355.44K | $3.17M | $1.24M | $969.83K | $1.23M | $368.90K | $-16.33K | $-310.96K | $-353.48K |
| Other Working Capital | $-1.08M | $803.20K | $487.92K | $-959.24K | $-934.06K | $944.53K | $850.04K | $-666.00K | $355.87K | $1.33M | $56.22K | $-69.24K | $105.91K | $169.92K | $-229.96K | $-754.32K |
| Other Non Cash Items | $4.48B | $-3.35B | $- | $627.49K | $12.25M | $22.82K | $82.96M | $22.05K | $1.01M | $231.12K | $-35.90K | $264.86K | $65.89K | $86.88K | $1.45M | $1.34M |
| Net Cash Provided by Operating Activities | $-4.48B | $-3.08B | $-1.91M | $-3.78M | $-2.79M | $-936.39K | $-407.62K | $-4.59M | $-416.31K | $-388.86K | $-315.52K | $-373.95K | $-616.19K | $-698.36K | $-1.50M | $-2.26M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-75.75M | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $2.70M | $- | $- | $-2.70M | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $2.70M | $- | $- | $-2.70M | $-75.75M | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $430.90M | $-316.00M | $79.20M | $2.67M | $5.00M | $2.52M | $395.20M | $-34.67K | $512.88K | $959.20K | $1 | $393.30K | $78.18M | $- | $22.06K | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $-1 | $-230.00K | $-10.47M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $3.03B | $2.93B | $- | $2.67M | $-653.33K | $187.37K | $-11.11M | $-34.67K | $1.06M | $662.80K | $296.40K | $812.62K | $-5.23M | $-63.80K | $750.56K | $5.23M |
| Net Cash Used Provided by Financing Activities | $3.03B | $2.93B | $- | $2.67M | $4.35M | $2.29M | $-641.76K | $-34.67K | $513 | $663 | $296 | $393 | $76.42M | $-63.80K | $750.56K | $5.23M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $-2.70M | $- | $- | $2.70M | $- | $- | $- | $- |
| Net Change in Cash | $1.41B | $2.98B | $-1.91M | $-1.10M | $1.56M | $1.35M | $-1.05M | $-4.62M | $96.57K | $273.94K | $-19.12K | $19.35K | $-616.19K | $-698.36K | $-1.50K | $2.97M |
| Cash at End of Period | $1.53B | $122.92M | $119.49K | $2.03M | $3.14M | $1.58M | $228.69K | $1.28M | $699.32K | $602.75K | $328.81K | $347.93K | $328.58K | $944.77K | $1.64K | $3.14K |
| Cash at Beginning of Period | $122.92M | $-2.86B | $2.03M | $3.14M | $1.58M | $228.69K | $1.28M | $5.90M | $602.75K | $328.81K | $347.93K | $328.58K | $944.77K | $1.64M | $3.14K | $-2.97M |
| Operating Cash Flow | $-4.48B | $-3.08B | $-1.91M | $-3.78M | $-2.79M | $-936.39K | $-407.62K | $-4.59M | $-416.31K | $-388.86K | $-315.52K | $-373.95K | $-616.19K | $-698.36K | $-1.50M | $-2.26M |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-4.48B | $-3.08B | $-1.91M | $-3.78M | $-2.79M | $-936.39K | $-407.62K | $-4.59M | $-416.31K | $-388.86K | $-315.52K | $-373.95K | $-616.19K | $-698.36K | $-1.50M | $-2.26M |
ZyVersa Therapeutics Dividends
Explore ZyVersa Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
ZyVersa Therapeutics News
Read the latest news about ZyVersa Therapeutics, including recent articles, headlines, and updates.
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative).
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
Inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function in obesity-associated cardiomyopathy.
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model
WESTON, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published data demonstrating that NLRP3 Inhibition attenuates development of AD pathology (buildup of Aβ) and neuroinflammation in a mouse model of AD, thereby attenuating disease progression.
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
WESTON, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today announced that it has entered into a securities purchase agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 2,105,265 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,105,265 shares of common stock at an effective combined price of $0.95 per share and common warrant for aggregate gross proceeds of approximately $2.0 million, before deducting placement agent fees and other offering expenses.
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
Heart failure with preserved ejection fraction (HFpEF), a chronic inflammatory condition, is a leading cause of morbidity and mortality globally. Obesity, diabetes, and hypertension are highly prevalent in this population and usually precede HFpEF development.
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025. New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells. Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development of type 2 diabetes.
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders. With weight loss, less inflammation is expected, but adipose tissue inflammation can persist long after weight loss.
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases The newly published data show that obesity leads to progressive brain inflammation in a mouse model, and that the proinflammatory processes worsen with prolonged obesity and with increased age This research supports our selection of obesity with associated comorbidities as the lead indication for Inflammasome ASC Inhibitor IC 100 IC 100 inhibits intra- and extracellular ASC and specks associated with multiple types of inflammasomes to attenuate damaging neurologic and systemic inflammation WESTON, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in the peer-reviewed journal, Aging Cell, demonstrating that obesity in older adults or prolonged duration of obesity in the younger population resulted in inflammation and suppression of neurotrophic/neuroprotective factors in the brain, indicating that age and duration of obesity are critical risk factors for neurodegenerative diseases.
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that Stephen C.
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four leading inflammasome experts and inventors of IC 100 from University of Miami Miller School of Medicine who have provided ongoing scientific advisory support for IC 100 since its license. WESTON, Fla.
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100.
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
Data demonstrate that extracellular ASC specks, independent of IL-1β, govern the pathogenesis and extent of amyloid A (AA) amyloidosis, which is characterized by deposition of insoluble amyloid fibrils in tissues and organs disrupting their structure and function. Extracellular ASC interacts with serum amyloid A (SAA) released by the liver during inflammation, forming a scaffold that accelerates SAA aggregation into amyloid fibrils, which are deposited in tissues and organs.
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on elevated ASC levels in older adults (>60 years) who were cognitively normal at baseline but demonstrated cognitive decline one year later (NI) compared to ASC levels in those who: Were cognitively normal at both baseline and 1 year later (NN), and Were cognitively impaired at both baseline and one year later (II) Inflammasome-induced neuroinflammation has been associated with early stages of cognitive decline in dementia associated with Alzheimer's and Parkinson's diseases. Excessive inflammasome activation leads to cell death (pyroptosis) and systemic release of cell contents, including ASC that can be measured in the plasma.
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that obesity and its related metabolic complications has been selected as the lead indication for Inflammasome ASC Inhibitor IC 100.
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
Publication showed that IC 100 suppressed retinal microglia activation by interfering with ASC speck formation, attenuating retinal inflammation, abnormal retinal vascularization, and retinal thinning, and it led to restored retinal function. Retinopathy of Prematurity (ROP), affecting very low birth weight premature infants is a leading cause of childhood blindness worldwide.
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Phase 2a Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of obesity and its associated metabolic complications, among other inflammatory diseases. Mr. Glover welcomes one-on-one meetings with registered participants.
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease planned to begin H1-2024. GLP toxicology studies for Inflammasome ASC Inhibitor IC 100 scheduled to begin H1-2024, with planned Investigational New Drug (IND) submission Q4-2024, and Phase 1 clinical trial initiation Q1-2025.Atherosclerosis preclinical data readout for Inflammasome ASC Inhibitor IC 100 on schedule for H1-2024.
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease
NLRP1 & pyrin govern inflammation in Alzheimer's Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation.
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide. The published data show that inhibiting the NLRP3 inflammasome pathway significantly reduces atherosclerotic lesions and improves hyperglycemic-induced plaque instability.
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024. Inflammasome ASC Inhibitor IC 100 preclinical program nearing completion, with planned Investigational New Drug (IND) submission Q4-2024, and Phase 1 clinical trial initiation shortly thereafter.
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
Phase 2a trial is on track to begin in the first half of 2024. Cholesterol Efflux Mediator TM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to chronic kidney disease and its progression.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
WESTON, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announces that on February 26, 2024, the company generated approximately $2.7 Million from existing investors' exercise of previously issued warrants. This was following excitement around news issued by NodThera on February 19, 2024, that their NLRP3 inflammasome inhibitors have potential to treat obesity with weight loss efficacy similar to the GLP-1 receptor agonist, Wegovy, but with added cardiovascular benefits. This news became viral among financial reporters, driving high volume trading and increased stock prices for companies developing inflammasome inhibitors, including ZyVersa.
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.
Should You Sell Your Penny Stocks? 3 Tips for When to Sell
Investing in penny stocks offers a unique opportunity for investors looking to expand their portfolios with potentially high-reward options. Recognized for their affordability, these stocks allow individuals to purchase shares in emerging companies without a significant financial outlay.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ZVSA.